- Home
- ALDX vs NPCT Comparison
ALDX vs NPCT Comparison
Compare ALDX & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- NPCT
- Stock Information
- Founded
- ALDX 2004
- NPCT 2020
- Country
- ALDX United States
- NPCT United States
- Employees
- ALDX N/A
- NPCT N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- ALDX Health Care
- NPCT Finance
- Exchange
- ALDX Nasdaq
- NPCT Nasdaq
- Market Cap
- ALDX 304.9M
- NPCT 311.7M
- IPO Year
- ALDX 2014
- NPCT N/A
- Fundamental
- Price
- ALDX $6.71
- NPCT $10.67
- Analyst Decision
- ALDX Strong Buy
- NPCT
- Analyst Count
- ALDX 2
- NPCT 0
- Target Price
- ALDX $10.00
- NPCT N/A
- AVG Volume (30 Days)
- ALDX 666.8K
- NPCT 107.1K
- Earning Date
- ALDX 05-01-2025
- NPCT 01-01-0001
- Dividend Yield
- ALDX N/A
- NPCT 9.82%
- EPS Growth
- ALDX N/A
- NPCT N/A
- EPS
- ALDX N/A
- NPCT N/A
- Revenue
- ALDX N/A
- NPCT N/A
- Revenue This Year
- ALDX N/A
- NPCT N/A
- Revenue Next Year
- ALDX N/A
- NPCT N/A
- P/E Ratio
- ALDX N/A
- NPCT N/A
- Revenue Growth
- ALDX N/A
- NPCT N/A
- 52 Week Low
- ALDX $2.75
- NPCT $8.58
- 52 Week High
- ALDX $7.20
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- ALDX 57.30
- NPCT 39.59
- Support Level
- ALDX $6.22
- NPCT $10.64
- Resistance Level
- ALDX $7.20
- NPCT $10.72
- Average True Range (ATR)
- ALDX 0.53
- NPCT 0.10
- MACD
- ALDX -0.01
- NPCT -0.03
- Stochastic Oscillator
- ALDX 79.59
- NPCT 6.19
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.